Moderna Climbs as S&P 500 Set to Welcome Covid Vaccine Maker
This article is for subscribers only.
Moderna Inc. climbed more than 6% in extended trading Thursday after the vaccine maker was named to the S&P 500 Index in one of the most noteworthy additions to the index since Tesla Inc. joined late last year.
The company, whose messenger-RNA vaccine has helped to fight the Covid-19 pandemic, will replace Alexion Pharmaceuticals Inc. in the benchmark U.S. index before the opening of trading on July 21. Alexion is set to be acquired by U.K. drugmaker AstraZeneca Plc.